These acquisitions advance Inscripta’s strategy to develop and commercialize biomanufactured products for a broad spectrum of industrial and consumer markets. They also demonstrate Inscripta’s confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation.
Inscripta is a life science technology company committed to creating a cleaner, healthier and more sustainable world through biomanufacturing. It focuses on the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing and spur new, safe and secure biotech innovations.
With these deals, Cooley continues to strengthen its presence in Colorado. In 2022, Cooley advised ColdQuanta on its $110 million Series B funding, and the company was featured on Time magazine’s Best Inventions of 2022 list.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
